Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2021 - 06 - 11 crawled time : 08:00 save search
Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival
Published: 2021-06-11 (Crawled : 08:00) - prnewswire.com
SRRA | $54.99 0.04% 0.0%
|
Health Technology
|
| O: 2.26%
H: 0.0%
C: -0.78%
presentation europe
Cheetah Mobile Announces First Quarter 2021 Unaudited Consolidated Financial Results
Published: 2021-06-11 (Crawled : 08:00) - prnewswire.com
CMCM | $4.06 8.85% 1.97% 66K
|
Technology Services
|
| O: -2.9%
H: 2.61%
C: -12.69%
financial results results mobile
Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome
Published: 2021-06-11 (Crawled : 08:00) - biospace.com/
SRPT | $117.065 0.09% 0.09% 440K
|
Health Technology
|
| O: -0.86%
H: 0.91%
C: 0.0%
treatment gene therapy therapy license gene therapies syndros
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.0%
H: 0.1%
C: -0.71%
XFOR | $1.225 -9.93% -11.02% 3.5M
|
Health Technology
|
| O: -1.8%
H: 0.97%
C: -5.51%
presentation ongoing phase 1 positive trial phase 1b phase 2b
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -3.51%
phase 2 positive results europe positive results
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: -0.61%
treatment blood therapy rare
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
AGIO | $31.82 5.33% 5.06% 1.2M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: -3.51%
europe phase 3
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
treatment potential anemia
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -2.59%
disease europe oxbryta potential children
Capital increase in TORM in connection with delivery of vessel
Published: 2021-06-11 (Crawled : 08:00) - globenewswire.com
TRMD | $35.33 -1.4% -1.42% 850K
|
Transportation
|
| O: 0.0%
H: 0.11%
C: -0.22%
liver
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.